Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis-Reference-Cited by-同舟云学术

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis

Published:2024-01-24 Issue:1 Volume:2024 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Al Said Samer¹,Kaier Klaus²,Sumaya Wael³,Alsaid Dima⁴,Duerschmied Daniel⁵⁶,Storey Robert F⁷,Gibson C. Michael⁸,Westermann Dirk¹,Alabed Samer⁷

Affiliation:

1. Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen; Faculty of Medicine, University of Freiburg; Freiburg Germany

2. Institute for Medical Biometry and Statistics; Faculty of Medicine and Medical Center, University of Freiburg; Freiburg Germany

3. Department of Medicine, Faculty of Medicine; Dalhousie University, QE II Health Sciences Centre, Halifax Infirmary; Halifax Canada

4. Institute for Evidence in Medicine, Medical Center – University of Freiburg; Faculty of Medicine, University of Freiburg; Freiburg Germany

5. Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care; University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University; Mannheim Germany

6. European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, Mannheim, Germany; Mannheim Germany

7. Department of Infection, Immunity and Cardiovascular Disease; University of Sheffield; Sheffield UK

8. Cardiology Division, Beth Israel Deaconess Medical Center; Harvard Medical School; Boston MA USA

Publisher

Wiley

Subject

Pharmacology (medical)

Reference140 articles.

1. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial;Alexander;Circulation,2009

2. Safety study of apixaban in recent acute coronary syndrome clinicaltrials.gov/show/NCT00313300

3. Apixaban with antiplatelet therapy after acute coronary syndrome;Alexander;New England Journal of Medicine,2011

4. Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial;Cornel;European Heart Journal,2012

5. Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: insights from the APixaban for PRevention of Acute ISchemic Events 2 trial;Cornel;American Heart Journal,2015